These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 12355680)

  • 41. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder.
    Volavka J; Czobor P; Sheitman B; Lindenmayer JP; Citrome L; McEvoy JP; Cooper TB; Chakos M; Lieberman JA
    Am J Psychiatry; 2002 Feb; 159(2):255-62. PubMed ID: 11823268
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The effect of risperidone on cognition in patients with schizophrenia.
    Stip E; Lussier I
    Can J Psychiatry; 1996 Oct; 41(8 Suppl 2):S35-40. PubMed ID: 8899249
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A prospective, open-label study to evaluate symptomatic remission in schizophrenia with risperidone long-acting injectable in Korea.
    Lee NY; Kim SH; Cho SJ; Chung YC; Jung IK; Kim CY; Kim DH; Lee DG; Lee YH; Lim WJ; Na YS; Shin SE; Woo JM; Yoon JS; Yoon BH; Ahn YM; Kim YS
    Int Clin Psychopharmacol; 2014 Sep; 29(5):279-87. PubMed ID: 24583566
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Sexual functioning associated with quetiapine switch vs. risperidone continuation in outpatients with schizophrenia or schizoaffective disorder: a randomized double-blind pilot trial.
    Byerly MJ; Nakonezny PA; Rush AJ
    Psychiatry Res; 2008 May; 159(1-2):115-20. PubMed ID: 18295343
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effect of olanzapine and risperidone on subjective well-being and craving for cannabis in patients with schizophrenia or related disorders: a double-blind randomized controlled trial.
    van Nimwegen LJ; de Haan L; van Beveren NJ; van der Helm M; van den Brink W; Linszen D
    Can J Psychiatry; 2008 Jun; 53(6):400-5. PubMed ID: 18616861
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Challenging the assumption that improvement in functional outcomes is delayed relative to improvement in symptoms in the treatment of schizophrenia.
    Kinon BJ; Chen L; Ascher-Svanum H; Stauffer VL; Kollack-Walker S; Zhou W; Kapur S; Kane JM; Naber D
    Schizophr Res; 2010 May; 118(1-3):176-82. PubMed ID: 20080036
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy and tolerability of a new antipsychotic compound (risperidone): results of a pilot study.
    Möller HJ; Pelzer E; Kissling W; Riehl T; Wernicke T
    Pharmacopsychiatry; 1991 Nov; 24(6):185-9. PubMed ID: 1725925
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder.
    Conley RR; Mahmoud R
    Am J Psychiatry; 2001 May; 158(5):765-74. PubMed ID: 11329400
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Agonist-like or antagonist-like treatment for cocaine dependence with methadone for heroin dependence: two double-blind randomized clinical trials.
    Grabowski J; Rhoades H; Stotts A; Cowan K; Kopecky C; Dougherty A; Moeller FG; Hassan S; Schmitz J
    Neuropsychopharmacology; 2004 May; 29(5):969-81. PubMed ID: 15039761
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia.
    Goff DC; Lamberti JS; Leon AC; Green MF; Miller AL; Patel J; Manschreck T; Freudenreich O; Johnson SA
    Neuropsychopharmacology; 2008 Feb; 33(3):465-72. PubMed ID: 17487227
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Risperidone in treatment-refractory schizophrenia.
    Wirshing DA; Marshall BD; Green MF; Mintz J; Marder SR; Wirshing WC
    Am J Psychiatry; 1999 Sep; 156(9):1374-9. PubMed ID: 10484947
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia.
    Casey DE; Daniel DG; Wassef AA; Tracy KA; Wozniak P; Sommerville KW
    Neuropsychopharmacology; 2003 Jan; 28(1):182-92. PubMed ID: 12496955
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The effects of pioglitazone adjuvant therapy on negative symptoms of patients with chronic schizophrenia: a double-blind and placebo-controlled trial.
    Iranpour N; Zandifar A; Farokhnia M; Goguol A; Yekehtaz H; Khodaie-Ardakani MR; Salehi B; Esalatmanesh S; Zeionoddini A; Mohammadinejad P; Zeinoddini A; Akhondzadeh S
    Hum Psychopharmacol; 2016 Mar; 31(2):103-12. PubMed ID: 26856695
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Long-acting risperidone vs. placebo in the treatment of hospital inpatients with schizophrenia.
    Lauriello J; McEvoy JP; Rodriguez S; Bossie CA; Lasser RA
    Schizophr Res; 2005 Jan; 72(2-3):249-58. PubMed ID: 15560969
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic.
    Kane JM; Eerdekens M; Lindenmayer JP; Keith SJ; Lesem M; Karcher K
    Am J Psychiatry; 2003 Jun; 160(6):1125-32. PubMed ID: 12777271
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Initial treatment of severe acute psychosis with fast orally disintegrating risperidone tablets.
    Normann C; Schmauss M; Bakri N; Gerwe M; Schreiner A
    Pharmacopsychiatry; 2006 Nov; 39(6):209-12. PubMed ID: 17124642
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Manic and psychotic symptoms following risperidone withdrawal in a schizophrenic patient.
    Lane HY; Chang WH
    J Clin Psychiatry; 1998 Nov; 59(11):620-1. PubMed ID: 9862609
    [No Abstract]   [Full Text] [Related]  

  • 58. [Initial use of risperidone in the treatment of acutely exacerbated schizophrenic patients--an interim analysis].
    Pajonk FG; Schreiner A; Peters S; Rettig K; Degner D; Rüther E
    Fortschr Neurol Psychiatr; 2003 May; 71(5):249-54. PubMed ID: 12740756
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Memantine add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized, double-blind, placebo-controlled study.
    Rezaei F; Mohammad-Karimi M; Seddighi S; Modabbernia A; Ashrafi M; Salehi B; Hammidi S; Motasami H; Hajiaghaee R; Tabrizi M; Akhondzadeh S
    J Clin Psychopharmacol; 2013 Jun; 33(3):336-42. PubMed ID: 23609382
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A placebo controlled study of the propentofylline added to risperidone in chronic schizophrenia.
    Salimi S; Fotouhi A; Ghoreishi A; Derakhshan MK; Khodaie-Ardakani MR; Mohammadi MR; Noorbala AA; Ahmadi-Abhari SA; Hajiazim M; Abbasi SH; Akhondzadeh S
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr; 32(3):726-32. PubMed ID: 18096287
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.